Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas

Video

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

CAR T-cell therapy is currently FDA-approved for patients with aggressive lymphoma subtypes, such as diffuse large B-cell lymphoma, primary mediastinal lymphoma, and other high-grade lymphomas. These patients are typically eligible for CAR T cell-therapy after having developed resistance to prior 2 lines of treatment. Galal says that approximately 40% of patients will progress on frontline R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride), and only 30% of those patients will benefit from an autologous stem cell transplant. Thus, CAR T cells can make a difference in a fairly large population of patients that had once represented an unmet need.

This approach has provided new hope for these patients in the third-line setting, he concludes.

Related Videos
Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
© 2024 MJH Life Sciences

All rights reserved.